Goldilocks Therapeutics, Inc.
Arthur Klausner is CEO of Goldilocks Therapeutics, Inc., a start-up focused on targeted renal drug delivery, initially to prevent/treat acute kidney injury. He was previously CEO of Gem Pharmaceuticals (acquired by Monopar Therapeutics in 2017) and CEO of Jade Therapeutics (acquired by EyeGate Pharmaceuticals in 2016). Prior to his operating roles, Klausner spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures. In addition to Goldilocks and Monopar, he currently serves on the Board of Directors of Cennerv Pharma (Singapore) and on Advisory Boards for Neurotez, the New York University Innovation Venture Fund, and 1st Pitch Life Science.